Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-495 (KeyImPaCT) biomarker-directed pembrolizumab-based combinations in advanced NSCLC
jRCT2080224552Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 2, open-label trial of pembrolizumab, lenvatinib, favezelimab and quavonlimab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Primary endpoint: Objective response rate (ORR). Started Feb 2019; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224552.